Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Abstract Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of naïve T cells in the lymphoid organs. Recently, we re...

Full description

Bibliographic Details
Main Authors: Fei Tang, Xuexiang Du, Mingyue Liu, Pan Zheng, Yang Liu
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Cell & Bioscience
Subjects:
CTLA-4
Ipilimumab
B7-CTLA-4 interaction
Regulatory T cells
Tumor microenvironment
Cancer immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13578-018-0229-z

Internet

http://link.springer.com/article/10.1186/s13578-018-0229-z

Similar Items